nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

09.01.2024 | Original Article

A bis-boron boramino acid PET tracer for brain tumor diagnosis

verfasst von: Zhu Li, Junyi Chen, Ziren Kong, Yixin Shi, Mengxin Xu, Bo-Shuai Mu, Nan Li, Wenbin Ma, Zhi Yang, Yu Wang, Zhibo Liu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Boramino acids are a class of amino acid biomimics that replace the carboxylate group with trifluoroborate and can achieve the ¹⁸F-labeled positron emission tomography (PET) and boron neutron capture therapy (BNCT) with identical chemical structure.

Methods

This study reports a trifluoroborate-derived boronophenylalanine (BBPA), a derived boronophenylalanine (BPA) for BNCT, as a promising PET tracer for tumor imaging.

Results

Competition inhibition assays in cancer cells suggested the cell accumulation of [¹⁸F]BBPA is through large neutral amino acid transporter type-1 (LAT-1). Of note, [¹⁸F]BBPA is a pan-cancer probe that shows notable tumor uptake in B16-F10 tumor-bearing mice. In the patients with gliomas and metastatic brain tumors, [¹⁸F]BBPA-PET shows good tumor uptake and notable tumor-to-normal brain ratio (T/N ratio, 18.7 ± 5.5, n = 11), higher than common amino acid PET tracers. The [¹⁸F]BBPA-PET quantitative parameters exhibited no difference in diverse contrast-enhanced status (P = 0.115–0.687) suggesting the [¹⁸F]BBPA uptake was independent from MRI contrast-enhancement.

Conclusion

This study outlines a clinical trial with [¹⁸F]BBPA to achieve higher tumor-specific accumulation for PET, provides a potential technique for brain tumor diagnosis, and might facilitate the BNCT of brain tumors.

Nur mit Berechtigung zugänglich

Liu Z, Chen H, Chen K, Shao Y, Kiesewetter DO, Niu G, et al. Boramino acid as a marker for amino acid transporters. Sci Adv. 2015;1:e1500694.CrossRefPubMedPubMedCentral

Li Z, Kaiser L, Holzgreve A, Ruf VC, Suchorska B, Wenter V, et al. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics. Eur J Nucl Med Mol Imag. 2021;48:4415–25.CrossRef

Heinzel A, Stock S, Langen K-J, Müller D. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imag. 2012;39:1089–96.CrossRef

Harat M, Rakowska J, Harat M, Szylberg T, Furtak J, Miechowicz I, et al. Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma. Nat Commun. 2023;14:4572.CrossRefPubMedPubMedCentral

Langen K-J, Watts C. Amino acid PET for brain tumours — ready for the clinic? Nat Rev Neurol. 2016;12:375–6.CrossRefPubMed

Li J, Shi Y, Zhang Z, Liu H, Lang L, Liu T, et al. A metabolically stable Boron-Derived Tyrosine serves as a Theranostic Agent for Positron Emission Tomography guided Boron Neutron capture Therapy. Bioconjug Chem. 2019;30:2870–8.CrossRefPubMed

Lan X, Fan K, Cai W. First-in-human study of an (18)F-labeled boramino acid: a new class of PET tracers. Eur J Nucl Med Mol Imaging. 2021;48:3037–40.CrossRefPubMedPubMedCentral

Li Z, Kong Z, Chen J, Li J, Li N, Yang Z, et al. 18F-Boramino acid PET/CT in healthy volunteers and glioma patients. Eur J Nucl Med Mol Imaging. 2021;48:3113–21.CrossRefPubMed

Kong Z, Li Z, Chen J, Ma W, Wang Y, Yang Z, et al. Larger 18F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors. EJNMMI Res. 2022;12:22.CrossRefPubMedPubMedCentral

10.

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170–86.CrossRefPubMed

11.

Wen PY, Reardon DA. Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016;12:69–70.CrossRefPubMed

12.

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma Nat Rev Dis Primers. 2015;1:15017.CrossRefPubMed

13.

Havu-Aurén K, Kiiski J, Lehtiö K, Eskola O, Kulvik M, Vuorinen V, et al. Uptake of 4-borono-2-[18 F] fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET. Eur J Nucl Med Mol Imag. 2007;34:87–94.CrossRef

14.

Nariai T, Ishiwata K, Kimura Y, Inaji M, Momose T, Yamamoto T, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot. 2009;67:348–S50.CrossRef

15.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231–51.CrossRefPubMedPubMedCentral

16.

Kong Z, Li Z, Chen J, Liu S, Liu D, Li J et al. Metabolic characteristics of [18F]fluoroboronotyrosine (FBY) PET in malignant brain tumors. Nucl Med Biol. 2022;106–7:80–7.

17.

Kong Z, Zhang Y, Liu D, Liu P, Shi Y, Wang Y, et al. Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas. Ann Nucl Med. 2021;35:493–503.CrossRefPubMed

18.

Chen J, Li C, Hong H, Liu H, Wang C, Xu M, et al. Side chain optimization remarkably enhances the in vivo stability of 18F-labeled glutamine for tumor imaging. Mol Pharm. 2019;16:5035–41.CrossRefPubMed

19.

Wollring MM, Werner J-M, Ceccon G, Lohmann P, Filss CP, Fink GR, et al. Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas. J Neurooncol. 2023;162:481–8.CrossRefPubMed

20.

Rozenblum L, Zaragori T, Tran S, Morales-Martinez A, Taillandier L, Blonski M, et al. Differentiating high-grade glioma progression from treatment-related changes with dynamic [18F]FDOPA PET: a multicentric study. Eur Radiol. 2023;33:2548–60.CrossRefPubMed

21.

Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392:432–46.CrossRefPubMed

22.

Bi JF, Chowdhry S, Wu SH, Zhang WJ, Masui K, Mischel PS. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer. 2020;20:57–70.CrossRefPubMed

23.

Kim MM, Parolia A, Dunphy MP, Venneti S. Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nat Rev Clin Oncol. 2016;13:725–39.CrossRefPubMedPubMedCentral

24.

Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906–20.CrossRefPubMed

25.

Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–85.PubMed

26.

Deuschl C, Kirchner J, Poeppel TD, Schaarschmidt B, Kebir S, El Hindy N, et al. (11)C-MET PET/MRI for detection of recurrent glioma. Eur J Nucl Med Mol Imaging. 2018;45:593–601.CrossRefPubMed

27.

Nodwell MB, Yang H, Čolović M, Yuan Z, Merkens H, Martin RE, et al. 18F-Fluorination of Unactivated C–H bonds in branched aliphatic amino acids: direct synthesis of Oncological Positron Emission Tomography Imaging agents. J Am Chem Soc. 2017;139:3595–8.CrossRefPubMed

28.

Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol. 2013;15:341–51.CrossRefPubMedPubMedCentral

29.

Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11 C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049–58.CrossRefPubMed

30.

Galldiks N, Niyazi M, Grosu AL, Kocher M, Langen KJ, Law I, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro Oncol. 2021;23:881–93.CrossRefPubMedPubMedCentral

31.

Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of 10B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4:70.CrossRefPubMedPubMedCentral

32.

Miyatake S, Kawabata S, Yokoyama K, Kuroiwa T, Michiue H, Sakurai Y, et al. Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol. 2009;91:199–206.CrossRefPubMed

33.

Linz U. Boron neutron capture therapy for glioblastoma: is it worth pursuing? Technol Cancer Res Treat. 2008;7:83–8.CrossRefPubMed

Titel: A bis-boron boramino acid PET tracer for brain tumor diagnosis
verfasst von: Zhu Li
Junyi Chen
Ziren Kong
Yixin Shi
Mengxin Xu
Bo-Shuai Mu
Nan Li
Wenbin Ma
Zhi Yang
Yu Wang
Zhibo Liu
Publikationsdatum: 09.01.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06600-5

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A bis-boron boramino acid PET tracer for brain tumor diagnosis

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2024

Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1

Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer

Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin αvβ3

Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis

Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds

Impact on cardiovascular outcome of coronary revascularization-induced changes in ischemic perfusion defect and myocardial flow reserve